Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Expert Says RSV Shots Will Have Significant Clinical Impact, Urges Public Funding and NIP Inclusion
March 8, 2024
- JSMO Panelists Urge Measures to Lure US Biotechs to Fight Drug Loss
February 27, 2024
- Pneumococcal Jabs Help Curb Pediatric Emergency Visits: Pediatrician
February 26, 2024
- KOL Highlights Need for Further RSV Epidemiological Research in Japan
February 15, 2024
- Drug Loss Is Intensifying for Rare Cancers amid Rise of Biotech Developers: JSMO Director
February 5, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- National Geriatrics Center to Kick Off Leqembi Treatment on Feb. 13
January 25, 2024
- NCC Launches Investigator-Led Studies on 5 Unapproved, Off-Label Drugs for Pediatric, AYA Cancers
January 22, 2024
- Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
January 22, 2024
- Medical Interns Improperly Prescribe, Use GLP-1 Agent for Off-Label Purpose
December 18, 2023
- Japan Obesity Society Urges Attention to Suicidal Thoughts in Patients Who Use Wegovy
November 29, 2023
- Scientific Societies Urge Greater Caution for COVID Drug Use in Women of Childbearing Age
November 15, 2023
- Chemotherapy Society Urges Govt to Create Body to Spur Drug Discovery
October 31, 2023
- G1 Product Info Could Disappear after Withdrawal, PMDA Website Should Retain Posting: Pharmacist
October 11, 2023
- Flu Drug Spending Hits 48 Billion Yen in FY2017, NCGM Flags Cost-Effectiveness
October 10, 2023
- NCC Announces “No Placebo Initiative” for Cancer Trials
October 10, 2023
- Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
September 25, 2023
- Japan Society to Select Facilities to Use Luxturna; 10 Sites for Genetic Testing, 2 or 3 for Treatment
August 25, 2023
- Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
- NIID Researcher Contracts Typhoid Fever
August 21, 2023
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…